Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 11/20 | 0.94 |
| ▸ | ADRA2B known ✓ | P18089 | 11/20 | 0.94 |
| ▸ | ADRA2C known ✓ | P18825 | 11/20 | 0.94 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.94 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.94 |
| ▸ | TSHR | P16473 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.91 |
| ▸ | HTR7 | P34969 | 1/20 | 0.91 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmedetomidine SCHEMBL23498050 | 1.00 | ADRA2A (0.94) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Dexmedetomidine SCHEMBL29546835 | 0.97 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Dexmedetomidine SCHEMBL29363193 | 0.97 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Medetomidine SCHEMBL29945090 | 0.97 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Medetomidine SCHEMBL787407 | 0.97 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Dexmedetomidine SCHEMBL26433 | 0.97 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Dexmedetomidine SCHEMBL31048740 | 0.97 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Medetomidine SCHEMBL28305816 | 0.97 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Dexmedetomidine SCHEMBL29833189 | 0.95 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Medetomidine SCHEMBL2202289 | 0.95 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569501-B2 | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions | WASHINGTON UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| US-12501899-B2 | Mite infestation treatment | VETO-PHARMA (FR) | 2025-12-23 | — | — | US | disclosed |
| EP-4661680-A1 | COMPOSITION FOR CONTROLLING MITE INFESTATION | Veto-Pharma (FR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250359547-A1 | ALKOXYLATED ALKANOLS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | BASF SE (DE) | 2025-11-27 | — | — | US | disclosed |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| US-20250176548-A1 | POLYMERIC IMIDAZOLIUM COMPOUNDS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | BASF SE (DE) | 2025-06-05 | — | — | US | disclosed |
| CN-118973393-A | Polymeric imidazolium compounds for enhancing the activity of antimicrobial agents | 巴斯夫欧洲公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024165712-A1 | COMPOSITION FOR CONTROLLING MITE INFESTATION | VETO-PHARMA (FR) | 2024-08-15 | — | — | WO | disclosed |
| EP-4413861-A1 | COMPOSITION FOR CONTROLLING MITE INFESTATION | Veto-Pharma (FR) | 2024-08-14 | — | — | EP | disclosed |
| CN-115003159-B | Mite infestation treatment | 伟途制药公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-2616069-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL | Allergan, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2616066-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL FOR TREATING RETINAL DISEASES | Allergan, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| CN-103200941-A | Ester prodrugs of [3- (1- (1H-imidazol-4-yl) ethyl) -2-methylphenyl ] methanol for lowering intraocular pressure | ALLERGAN INC | 2013-07-10 | — | — | CN | disclosed |
| WO-2013078151-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2012067941-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012037453-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037484-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037499-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037490-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250359547-A1 | ALKOXYLATED ALKANOLS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | CAT, LPO, ALKBH1 | ADRA2A 2756/4885ADRA2B 3021/4885ADRA2C 2693/4885 |
| US-12569501-B2 | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions | ATG13, GSK3B, HSD11B1 | ADRA2A 89/4885ADRA2B 18/4885ADRA2C 76/4885 |
| US-12501899-B2 | Mite infestation treatment | RHOA, NPEPPS, TUBA3E | ADRA2A 3402/4885ADRA2B 3269/4885ADRA2C 2479/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | ADRA2A 7/4885ADRA2B 5/4885ADRA2C 8/4885 |
| US-20250176548-A1 | POLYMERIC IMIDAZOLIUM COMPOUNDS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | MPO, MIF, ARG1 | ADRA2A 4741/4885ADRA2B 4628/4885ADRA2C 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.